iPPI-DB

Inhibitors of Protein-Protein Interaction Database

Compound 2093

Identifiers

  • Canonical SMILES: 
    CC[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@](C)(CCCCN(C)C(=O)[C@H](NC1=O)c1ccc(Cl)cc1)NC(=O)C(C)C
  • IUPAC name: 
    N-[(3R,6S,9S,12R)-9-(3-carbamimidamidopropyl)-3-(4-chlorophenyl)-6-ethyl-1,12-dimethyl-2,5,8,11-tetraoxo-1,4,7,10-tetraazacyclohexadecan-12-yl]-2-methylpropanamide
  • InChi: 
    InChI=1S/C30H47ClN8O5/c1-6-21-25(41)37-23(19-11-13-20(31)14-12-19)27(43)39(5)17-8-7-15-30(4,38-24(40)18(2)3)28(44)36-22(26(42)35-21)10-9-16-34-29(32)33/h11-14,18,21-23H,6-10,15-17H2,1-5H3,(H,35,42)(H,36,44)(H,37,41)(H,38,40)(H4,32,33,34)/t21-,22-,23+,30+/m0/s1
  • InChiKey: 
    KXYGAIVJVQJFDQ-CXDLDTBJSA-N

External links


71585983
CHEMBL4116506

External search

Bibliography (1)

Publication Name
Karatas Hacer, Li Yangbing, Liu Liu, Ji Jiao, Lee Shirley, Chen Yong, Yang Jiuling, Huang Liyue, Bernard Denzil, Xu Jing, Townsend Elizabeth C., Cao Fang, Ran Xu, Li Xiaoqin, Wen Bo, Sun Duxin, Stuckey Jeanne A, Lei Ming, Dou Yali, Wang Shaomeng. . Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)–Mixed Lineage Leukemia (MLL) Protein–Protein Interaction Journal of Medicinal Chemistry. 5

Pharmacological data

Biochemical tests Cellular tests PK tests Cytotoxicity tests
3 0 0 0

Targets

PPI family Best activity Diseases MMoA
WDR5/MLL 9.00 lymphoid leukemia (disease) Inhibition
Physicochemical filters
Descriptor Lipinski's RO5 Veber Pfizer's 3/75
Compliance
MW 634.34 g/mol
HBA 13
HBD 8
HBA + HBD 21
AlogP 0.50
TPSA 200.35
RB 8
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 3 0 0 0
Pharmacological data
Bibliography Name Target Competition Assay type Assay name Cell line Activity type Activity
10.1021/acs.jmedchem.6b01796 5 KMT2A
Q03164 		WDR5
P61964 		Biochemical assay Fluorescence Polarization pIC50 (half maximal inhibitory concentration, -log10) 8.82
10.1021/acs.jmedchem.6b01796 5 KMT2A
Q03164 		WDR5
P61964 		Biochemical assay Fluorescence Polarization pKi (inhibition constant, -log10) 9.00
10.1021/acs.jmedchem.6b01796 5 KMT2A
Q03164 		WDR5
P61964 		Biochemical assay AlphaLISA pIC50 (half maximal inhibitory concentration, -log10) 6.91
Ta Structure Name Drugbank ID
0.7054 CR665 DB05155
0.6937 3-cyclohexyl-D-alanyl-N-(3-chlorobenzyl)-L-prolinamide DB07190
0.6923 D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide DB06919
0.6789 1-[(2R)-2-aminobutanoyl]-N-(3-chlorobenzyl)-L-prolinamide DB06878
0.6789 D-leucyl-N-(3-chlorobenzyl)-L-prolinamide DB06911
0.6606 N-(3-chlorobenzyl)-1-(4-methylpentanoyl)-L-prolinamide DB06868
0.6579 D-phenylalanyl-N-benzyl-L-prolinamide DB07143
0.6500 D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide DB07005
0.6441 4-chloro-N-(3-methoxypropyl)-N-[(3S)-1-(2-phenylethyl)piperidin-3-yl]benzamide DB08344
0.6378 PZ-128 DB11839
0.6372 (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide DB06850
0.6372 N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide DB06858
0.6356 D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide DB07133
0.6339 1-[(2R)-2-aminobutanoyl]-N-(4-carbamimidoylbenzyl)-L-prolinamide DB06947
0.6339 D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide DB06996